Skip to main content
PREFER
  • About
  • Partners
  • Case studies
  • Publications
  • Stakeholders
  • News
  • Contact
  • Recommendations
PREFER
  • About
  • Case studies
  • Events
  • Stakeholders
  • News
  • Partners
  • People
  • Publications
    • PhD theses
    • Deliverables
    • Case study summaries
    • Data management
    • Authorship
    • Recommendations
  • Contact
  • Recommendations
PREFER Publications Deliverables
Listen
  • About
  • Case studies
  • Events
  • Stakeholders
  • News
  • Partners
  • People
  • Publications
    • PhD theses
    • Deliverables
    • Case study summaries
    • Data management
    • Authorship
    • Recommendations
  • Contact
  • Recommendations

Public PREFER deliverables

Patient preference studies can give valuable information to support decision making for regulators and HTA bodies. We have spent the last 5 years establishing recommendations to support development of guidelines for industry, Regulatory Authorities and HTA bodies on how and when to include patient perspectives on benefits and risks of medicinal products. 

Patient preference methodology

Desires, expectations, concerns and requirements of stakeholders about methodologies for patient-preference elicitation and their use in making well- informed decisions regarding medicinal products

Processes, conditions and contextual factors that influence the utility and role of patient preference studies

Identification of assessment criteria used at decision points throughout the medical product lifecycle

Identification of educational and psychological feature methods

Characterising and appraising the methods

Report on methods for measuring patient benefit-risk preferences in medical treatment

Identification of candidate methodologies and criteria to assess empirical case and simulation studies

Determine research questions and assessment criteria for the preference studies used in the empirical case studies

Designing and conducting clinical case studies

Translate the preliminary research questions identified in WP2 to concrete study design

Report on additional case studies

Last modified: 2022-02-03
Print

Contact us

contact@imi-prefer.eu

communications@imi-prefer.eu

Follow us on twitter: @IMI_PREFER or YouTube

Subscribe to our newsletter

Disclaimer: This website and its contents reflects the PREFER project's view and not the view of IMI, the European Union or EFPIA.


 

Shortcuts

About PREFER

Our Stakeholders

Partners

ProjectPlace login

Dissemination proposal form

Accessibility report for imi-prefer.eu

PREFER

The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

This site is hosted by Uppsala University